| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 21,811 | 13,826 |
| Stock-based compensation | 17,223 | 12,905 |
| Interest on liability for sale of future royalties | 10,564 | 7,052 |
| Sold portion of royalty revenue | 9,455 | 6,123 |
| Write-off of inventory | 8,335 | 5,058 |
| Depreciation and amortization | 6,254 | 4,193 |
| Loss on foreign currency transaction | -7,752 | -7,872 |
| Impairment loss on available-for-sale investment | -6,409 | - |
| Net accretion of investments | -2,245 | -1,678 |
| Amortization of right-of-use assets | 1,815 | 1,075 |
| Amortization of debt discount and issuance costs | 376 | 218 |
| Accounts receivable, net | 5,579 | 15,338 |
| Inventory | 7,421 | 5,663 |
| Prepaid expenses and other current assets | 12,360 | 5,371 |
| Other assets | 1,526 | 1,525 |
| Accounts payable | 477 | 3,465 |
| Accrued expenses and other current liabilities | -10,094 | -9,333 |
| Deferred revenue | -5,250 | -7,141 |
| Operating lease liabilities | -873 | -919 |
| Net cash provided by operating activities | 26,213 | 2,573 |
| Purchase of available-for-sale securities | 144,080 | 88,127 |
| Proceeds from maturities of available-for-sale securities | 143,812 | 101,792 |
| Issuance of note receivable | 10,000 | - |
| Purchase of property and equipment | 2,572 | 1,447 |
| Net cash used in investing activities | -12,840 | 12,218 |
| Proceeds from term loan | 75,000 | - |
| Payment of loan issuance costs | 2,347 | - |
| Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options | 5,136 | 4,393 |
| Principal payments on financing liability | 530 | 376 |
| Proceeds from market price stock purchase plan and employee stock purchase plan | 1,338 | 1,288 |
| Milestone payment | - | 639 |
| Milestone right agreement payment | 639 | - |
| Net cash provided by (used in) financing activities | 67,686 | -4,120 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 81,059 | 10,671 |
| Cash and cash equivalents at beginning of period | 47,076 | - |
| Cash and cash equivalents at end of period | 128,135 | - |
MANNKIND CORP (MNKD)
MANNKIND CORP (MNKD)